Current Report Filing (8-k)
December 23 2020 - 4:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report
(Date of earliest event reported): December 23, 2020
NeuBase
Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
|
|
001-35963
|
|
46-5622433
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
700 Technology Drive, Pittsburgh, PA
|
|
15219
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
(646)
450-1790
|
|
(Registrant's
Telephone Number, Including Area Code)
|
|
N/A
|
|
(Former
Name or Former Address, if Changed Since
Last Report)
|
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant
to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
NBSE
|
The
Nasdaq Stock Market LLC
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging growth company ¨
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item
2.02.
|
Results
of Operations and Financial Condition.
|
On December 23, 2020, NeuBase
Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended
September 30, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
In accordance with General Instructions
B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liability of that section, and shall not be incorporated by reference into any registration statement or other document filed
under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference
in such filing.
Item
9.01.
|
Financial
Statements and Exhibits.
|
(d) Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
NEUBASE THERAPEUTICS, INC.
|
|
(Registrant)
|
|
|
Date: December 23, 2020
|
By:
|
/s/ Sam Backenroth
|
|
|
Sam Backenroth
|
|
|
Chief Financial Officer
|
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Aug 2024 to Sep 2024
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Sep 2023 to Sep 2024